



04-10-03

RCE
#1600
#7/B
4/14/03
xa

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/905,484
Filing Date	July 13, 2001
First Named Inventor	Moncef Jendoubi
Group Art Unit	1641
Examiner Name	Gary W. Counts
Attorney Docket Number	705403.8 (L&L 252/159)

This is a Request for continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective May 29, 2000. If the above-identified was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patented term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. Previously submitted
 - i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
Any unentered amendment(s) referred to above will be entered.
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. Other _____
- b. Enclosed
 - i. Preliminary Amendment/Reply
 - ii. Affidavit(s)/Declarations(s)
 - iii. Information Disclosure Statement (IDS)
 - iv. Other _____; Return Postcard

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

2. Miscellaneous

- a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. Other _____

3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 150665
 - i. RCE fee required under 37 C.F.R. § 1.17(e) \$375.00
 - ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17); if any extension of time is required, please consider this a request therefor. \$205.00 (two months)
 - iii. Other: Any fee under \$1.15 or _____
- b. Check in the amount of \$ _____ enclosed
- c. Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Kurt T. Mulville	Registration No.	37,194
Signature		Dated	April 7, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print/Type)	Lynne Fulmer	Express Mail Tracking No.	EV 247496906 US
-------------------	--------------	---------------------------	-----------------

Signature		Date	April 7, 2003
-----------	--	------	---------------

04/11/2003 CV0111 00000052 150665 09905484

01 FC:2801 375.00 CH
02 FC:2252 205.00 CH

7A
NJ



Orrick No. 705403.8
(former L&L No. 252/159)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

File the Application of:

Moncef Jendoubi

Serial No.: 09/905,484

Filed: July 13, 2001

For: INFORMATION ENHANCED
ANTIBODY ARRAYS

) Group Art Unit: 1641

) Examiner: Gary W. Counts

PRELIMINARY AMENDMENT AND RESPONSE

Box RCE
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 11 2003

Sir:

Please amend the application as follows:

TECH CENTER 1600/2900

IN THE CLAIMS:

Please amend claims 1 and 15, as follows:

1. ~ An array of at least 10 different antibodies arranged in discrete areas of a solid support wherein each antibody specifically binds a different antigen and is correlated to expression of a polynucleotide sequence encoding the antigen.
- b1 *method step*

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EV 247496906 US
Express Mail Label No.

April 7, 2003
Date of Deposit
DOCSOC1:136083.1
705403-8 K2M

Lynne Fulmer
Name of Person Mailing Paper

Lynne Fulmer
Signature of Person Mailing Paper